Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.34
$0.2156.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.70% | -13.82% | -17.93% | 14.26% | -8.55% |
| Total Depreciation and Amortization | 1.22% | -2.38% | 1.20% | 0.00% | -22.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.20% | 3.51% | -34.66% | -6.91% | -14.44% |
| Change in Net Operating Assets | -252.79% | 35.08% | 323.62% | 156.55% | -239.65% |
| Cash from Operations | -58.07% | -10.36% | -9.72% | 25.94% | -19.30% |
| Capital Expenditure | -- | 100.00% | 85.45% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -359.16% | 176.58% | -1,079.40% | -87.01% | 59.11% |
| Cash from Investing | -359.35% | 176.56% | -1,097.96% | -87.25% | 59.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.57% | 130.90% | 33,231.85% | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | 90.79% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.85% | 86.55% | -207.23% | -- | -- |
| Cash from Financing | -98.23% | -- | -100.00% | 55,484.21% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -164.24% | 393.57% | -201.27% | 195.37% | 117.34% |